Luis Aurelio Díaz

Publications (2)2.17 Total impact

• Article: [Non-pharmacological prevention of ventilator-associated pneumonia].

  Luis Aurelio Díaz, Mireia Llauradó, Jordi Rello, Marcos I Restrepo
  [show abstract] [hide abstract]
  ABSTRACT: Ventilator-associated pneumonia (VAP) is the first cause of mortality due to nosocomial infections in the intensive care unit. Its incidence ranges from 9% to 67% of patients on mechanical ventilation. Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units. Additional costs for each episode of VAP range from 9,000 euro to 31,000 euro. Thus, its prevention should be considered as a priority. This prevention could decrease associated morbidity, mortality, costs, and increase patient safety.
  Archivos de Bronconeumología 10/2009; 46(4):188-95. · 2.17 Impact Factor
• Article: Non-Pharmacological Prevention of Ventilator Associated Pneumonia

  Luis Aurelio Díaz, Mireia Llauradó, Jordi Rello, Marcos I. Restrepo
  [show abstract] [hide abstract]
  ABSTRACT: Ventilator-associated pneumonia (VAP) is the first cause of mortality due to nosocomial infections in the intensive care unit. Its incidence ranges from 9% to 67% of patients on mechanical ventilation. Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units. Additional costs for each episode of VAP range from €9,000 to €31,000.Thus, its prevention should be considered as a priority. This prevention could decrease associated morbidity, mortality, costs, and increase patient safety.ResumenLa neumonía asociada a ventilación mecánica es la primera causa de mortalidad por infecciones nosocomiales en la unidad de cuidados intensivos. Su incidencia oscila entre el 9 y el 67% de los pacientes que requieren ventilación mecánica. Hay múltiples factores de riesgo asociados y aumenta significativamente la estancia en la unidad de cuidados intensivos y en el hospital. El coste adicional por cada neumonía asociada a ventilación mecánica oscila entre 9.000 y 31.000 €.Por tanto, su prevención debe considerarse una prioridad. Ésta podría disminuir tanto la morbimortalidad asociada como el coste de la atención, y mejorar la seguridad del paciente.
  Archivos de Bronconeumología ((English Edition)).